Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership
Summary
New Investors Take Over the Strategic Leadership as Headquarters Move to Bogot\xe1, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced GovernanceCompany Accelerates Turnaround with Leadership Changes, Regional Realignment, Sale of Non-Core Assets and Renewed GovernanceMIAMI and BOGOTA, Colombia, April 09, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (Procaps or the Company), a leading Latin America integrated pharmaceutical and healthcare company, announced today a major milestone in its transformation journey with the successful completion of a $130 million equity investment (including the previously announced secured convertible notes issued to Hoche Partners Pharma Holding S.A.) and the finalization of a comprehensive debt restructuring with its key lenders, marking a turning point in the Companys multi-phase transformation strategy, centered on growth, disciplined execution, and enhanced corporate governance.As part of this comprehensive restructuring, new strategic investors have formally taken over the leadership of the Company, bringing a renewed focus on operational excellence, financial discipline, and long-term value creation. This new leadership will be accompanied by the implementation of higher international standards in governance and compliance, including stronger internal controls and an enhanced culture of transparency and accountability.These achievements reinforce the Companys commitment to restoring financial health, improving operational performance, and rebuilding long-term growth under the leadership of a new investor group and a redesigned organizational structure.The private capital raise, comprised of a $90 million private placement of ordinary shares of Procaps and the issuance of $40 million in secured convertible notes during the end of 2024 and conversion of such notes into ordinary shares of Procaps, was secured from Chemo Project S.A., Becaril S.A., Flying Fish Ventures L.P., Saint Thomas Commercial S.A., Santana S.A., Hoche Partners Pharma Holding S.A. and other investors. Barranquilla remains a critical hub for the Companys innovation and production, and its role in driving the business forward remains unchanged.The headquarter relocation is part of a broader internal reorganization that includes: Centralization of Finance, FP&A, Compliance, Legal, IT and key support functions; Strengthening of internal controls, reporting, and operating discipline to support transparency and execution.To increase accountability and improve commercial performance, the Company is reorganizing its operations into five regional clusters: CENAM (Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, and the Dominican Republic formerly CAN and CASAND)Additionally, the Company continues to actively evaluate strategic alternatives for non-core assets. Several discussions are in advanced stages, with potential proceeds to be used for deleveraging and reinvestment in high-margin, strategic assets and operations.With a stronger capital structure, a simplified balance sheet, and renewed leadership, Procaps is now positioned to execute its transformation with discipline, clarity, and purpose.The Company is focused on: Reinforcing governance and transparency across all levels of the organization; Delivering on its remediation plan, and publishing financial results as soon as possible; Unlocking value through divestitures of non-core assets and focusing on high-margin, strategic segments; and Investing in innovation and commercial growth, with a focus on prescription drugs (Rx), and expanding its CDMO global footprint.While the path forward will continue to require hard decisions and sustained execution, the foundations for a turnaround are firmly in place. Such forward-looking statements with respect to revenues, earnings, performance, strategies, synergies, prospects, forecasts and other aspects of the businesses of Procaps are based on current expectations that are subject to risks and uncertainties.